

FORTHCOMING PAPERS IN THE JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Vol. 37, No. 6

The next issue of *The Journal of Steroid Biochemistry and Molecular Biology* will be a Special Issue consisting of papers from the *Proceedings of the 2nd International EORTC Symposium on "Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti-)Steroidal Agents"*, Rotterdam, The Netherlands, 9-11 April 1990.

I. Steroid Receptors and New (Anti-)Steroidal Agents

- S. GREEN: Modulation of oestrogen receptor activity by oestrogens and anti-oestrogens
P. D. DARBRE and R. J. DALY: Transition of human breast cancer cells from an estrogen responsive to unresponsive state
D. F. C. GIBSON, M. M. GOTTARDIS and V. C. JORDAN: Sensitivity and insensitivity of breast cancer to tamoxifen
A. E. WAKELING: Therapeutic potential of pure antiestrogens in the treatment of breast cancer
G. FREIS, C. PREBOIS, H. ROCHEFORT and F. VIGNON: Anti-steroidal and anti-growth factor activities of anti-estrogens
M. R. SCHNEIDER, H. MICHNA, Y. NISHINO and M. EL ETREBY: Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models
G. H. BAKKER, B. SETYONO-HAN, H. POTENGEN, F. H. DE JONG, J. A. FOEKENS and J. G. M. KLIJN: Treatment of breast cancer with different antiprogestins; preclinical and clinical studies.

II. Oncogenes and Growth Factors

- R. B. DICKSON: Stimulatory and inhibitory growth factors and breast cancer
C. K. OSBORNE, D. R. CLEMMONS and C. L. ARTEAGA: Regulation of breast cancer growth by insulin-like growth factors
S. NICHOLSON, C. WRIGHT, J. R. C. SAINSBURY, P. HALCROW, P. KELLY, B. ANGUS, J. R. FARNDON and A. L. HARRIS: Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients; neu and tamoxifen failure
J. A. FOEKENS, W. L. J. VAN PUTTEN, H. PORTENGEN, C. J. RODENBURG, J.-C. REUBI, P. M. J. J. BERNS, S. C. HENZEN-LOGMANS, M. E. L. VAN DER BURG, J. ALEXIEVA-FIGUSCH and J. G. M. KLIJN: Prognostic value of PS2 protein, and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R), and somatostatin (SS-R), in patients with breast and ovarian cancer
J. P. PEYRAT, J. BONNETERRE, P. H. VENNIN, H. JAMMES, R. BEUSCART, B. HECQUET, J. DJIANE, J. LEFEBVRE and A. DEMAILLE: Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors
A. H. BOOTSMA, A. DE KLEIN, J. C. REUBI, E. C. ZWARTHOF and S. W. J. LAMBERTS: Genetic changes in somatostatin receptor positive breast tumors
R. C. COOMBS, P. BARRETT-LEE and Y. LUQMANI: Growth factor expression in breast tissue
J. TRAPMAN, C. RIS-STALPERS, J. A. G. M. VAN DER KORPUT, G. G. J. M. KUIPER, P. W. FABER, J. C. ROMIJN, E. MULDER and A. O. BRINKMANN: The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines
P. S. RENNIE, N. BRUCHOVSKY and A. J. COLDMAN: Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance of cell-death genes
A. L. G. SCHUURMANS, J. BOLT, J. VELDSCHOLTE and E. MULDER: Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion
T. BAUKNECHT, G. BIRME LIN and F. KOMMOSS: Clinical significance of oncogenes and growth factors in ovarian carcinomas
F. H. DE JONG, A. J. GROOTENHUIS, J. STEENBERGEN, F. J. VAN SLUIJS, J. A. FOEKENS, F. J. W. TEN KATE, J. W. OOSTERHUIS, S. W. J. LAMBERTS and J. G. M. KLIJN: Inhibin immunoreactivity in gonadal and non-gonadal tumors
A. R. M. M. HERMUS and C. G. J. SWEEP: Cytokines and the hypothalamic-pituitary-adrenal axis
H. A. P. POLS, J. C. BIRKENHÄGER, J. A. FOEKENS and J. P. T. M. VAN LEEUWEN: Vitamin D: a modulator of cell proliferation and differentiation
K. HAVEMANN, M. ROTSCH, H.-J. SCHÖNEBERGER, C. ERBIL, C. HENNIG and G. JAQUES: Growth regulation by insulin-like growth factors in lung cancer
S. P. ROBINSON, W. C. ROSE and A. M. CASAZZA: *In vivo* evaluation of epidermal growth factor and transforming growth factor β_1 in mouse tumor models
J. MENDELSON: Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents
R. V. LA ROCCA, C. A. STEIN, R. DANESI and C. E. MYERS: Suramin, a novel antitumor compound
- ### *III. Hormonal Treatment of Prostate Cancer (in Honor of Professor H. J. de Voogt)*
- A. QAYUM, W. J. GULLICK, K. MELLON, T. KRAUSZ, D. NEAL, K. SIKORA and J. WAXMAN: The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cells lines
W. M. VAN WEERDEN, G. J. VAN STEENBRUGGE, A. VAN KREUNINGEN, E. P. C. M. MOERINGS, F. H. DE JONG and F. H. SCHRÖDER: Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice
M. NAMER, J. TOUBOL, L. ADENIS, J. E. COUETTE, J. DOUCHEZ, P. KERBRAT and J. P. DROZ: A randomized double-blind study evaluating Anandron® associated with orchiectomy in stage D prostate cancer
F. RASMUSSEN: Long-term treatment with antiandrogens
C. MAHLER and L. DENIS: Clinical profile of a new non-steroidal antiandrogen

J. SANDOW, K. STOECKEMANN and G. JERABEK-SANDOW: Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues

G. A. DIJKMAN, P. FERNANDEZ DEL MORAL, J. W. M. H. PLASMAN, J. J. M. KUMS, K. P. J. DELAERE, F. M. J. DEBRUYNE, F. J. HUTCHINSON and B. J. A. FURR: A new extra long acting depot preparation of the LHRH analogue Zoladex®

U.-F. HABENICHT, M. R. SCHNEIDER and M. FATHY EL ETREBY: Effect of the new potent LHRH antagonist Antide

F. LABRIE, A. DUPONT, L. CUSAN, J. GOMEZ, J. EMOND and G. MONFETTE: Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience

L. DENIS, M. ROBINSON, C. MAHLER, PH. SMITH, F. KEUPPENS, J. L. CARNEIRO DE MOURA, A. BONO, D. NEWLING, R. SYLVESTER, M. DE PAUW, K. VERMEYLEN, P. ONGENA and Members of the EORTC-GU Group: Orchidectomy versus Zoladex® plus Eulexin® in patients with metastatic prostate cancer (EORTC 30853)

E. D. CRAWFORD and J. A. ALLEN: Treatment of newly diagnosed stage D2 prostate cancer with Leuprolide and Flutamide or Leuprolide alone, phase III, intergroup study 0036

H. J. DE VOGT, J. G. M. KLIJN, U. STUDER, F. SCHRÖDER, R. SYLVESTER, M. DE PAUW and Members of the EORTC-GU Group: Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer

D. W. W. NEWLING, S. FOSSA, U. TUNN and K. H. KURTH: The comparison of the effects of high dose Estramustine phosphate and Mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group study No. 30865

IV. Peptide Hormones and Cancer

J. BONNETERRE, J. P. PEYRAT, R. BEUSCART and A. DEMAILLE: Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer

L. DOGLIOTTI, A. BERUTTI, T. BUNIVA, M. TORTA, A. BOTTINI, M. TAMPELLINI, M. TERZOLO, R. FAGGIUOLO and A. ANGELI: Melatonin and human cancer

R. I. NICHOLSON, K. J. WALKER, R. A. MCCLELLAND, A. DIXON, J. F. R. ROBERTSON and R. W. BLAMEY: Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer

P. G. SATYASWAROOP and R. MORTEL: Hormonal treatment of endometrial carcinoma: an overview and new development in biology

G. EMONS, G. S. PAHWA, O. ORTMANN, R. KNUPPEN, F. OBERHEUSER and K.-D. SCHULZ: LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview

C. N. D'ARVILLE and P. J. JOHNSON: Growth factors, endocrine aspects and hormonal treatment in hepatocellular carcinoma—an overview

V. Enzyme Inhibitors

P. F. BRUNING, J. M. G. BONFRÈR, J. WILDIERS, J. JASSEM, L. V. A. M. BEEEX, J. SCHORNAGEL and W. J. NOOIJEN: Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861)

A. S. BHATNAGER, A. HÄUSLER, K. SCHIEWECK, M. LANG and R. BOWMAN: Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new nonsteroidal aromatase inhibitor

R. J. SANTEN: Recent progress in development of aromatase inhibitors

M. DOWSETT: Aromatase inhibitors in the treatment of breast and prostate cancer

A. M. H. BRODIE, P. H. BANKS, S. E. INKSTER and R. KOOS: Aromatase and other inhibitors in breast and prostatic cancer

W. WOUTERS, R. DE COSTER, J. VAN DUN, M. D. W. G. KREKELS, A. DILLEN, A. RAEYMAEKERS, E. FREYNE, J. VAN GELDER, G. SANZ, M. VENET and M. JANSSEN: Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis *in vitro* and *in vivo*

W. R. MILLER, T. J. ANDERSON and W. J. L. JACK: Relationship between tumour aromatase activity, tumour characteristics and response to therapy

VI. Somatostatin Analogs and Cholecystokinin Inhibitors

A. V. SCHALLY, G. SRKALOVIC, B. SZENDE, T. W. REDDING, T. JANAKY, A. JUHASZ, E. KORKUT, R.-Z. CAI, K. SZEPESHAZI, S. RADULOVIC, L. BOKSER, K. GROOT, P. SERFOZO and A. M. COMARU-SCHALLY: Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies

C. B. H. W. LAMERS, J. B. M. J. JANSSEN and R. A. WOUTERSEN: Cholecystokinin and gastrointestinal cancer

J. C. REUBI, E. KRENNING, S. W. J. LAMBERTS and L. KVOLS: Somatostatin receptors in malignant tissues

S. W. J. LAMBERTS, W. H. BAKKER, J.-C. REUBI and E. P. KRENNING: Somatostatin receptor imaging. *In vivo* localization of tumors with a radiolabeled somatostatin analog

A. MANNI, A. E. BOUCHER, L. M. DEMERS, H. A. HARVEY, A. LIPTON, M. A. SIMMONDS and M. BARTHOLOMEW: Somatostatin analogues in the treatment of breast and prostate cancer

J. G. M. KLIJN, B. SETYONO-HAN, G. H. BAKKER, M. E. L. VAN DER BURG, M. BONTENBAL, H. A. PETERS, A. M. SIEUWERTS, P. M. J. J. BERNIS and J. A. FOEKENS: Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies

VII. Hormonal Recruitment and Chemotherapy

M. BONTENBAL, A. M. SIEUWERTS, H. A. PETERS, P. SONNEVELD, J. A. FOEKENS and J. G. M. KLIJN: Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells

P. F. CONTE, G. GARDIN, P. PRONZATO, L. MIGLIETTA, R. ROSSO, D. AMADORI, P. GENTILINI, C. MONZEGLIO, P. GALLOTTI, R. DEMICHELI, F. BREMA, P. SISMONDI, P. MICCOLI, C. LANFRANCO, F. MINUTO, A. BARRECA and P. DEL MONTE: *In vivo* manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and clinical results

R. PARIDAENS, J. C. HEUSON, J. P. JULIEN, C. VEYRET, J. VAN ZIJL, J. G. M. KLIJN, R. J. SYLVESTER, F. MIGNOLET and the EORTC Breast Cancer Cooperative Group: Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: preliminary results of a double-blind randomized study of the EORTC Breast Cancer Cooperative Group

R. J. SANTEN, A. MANNI, H. F. ENGLISH and D. HEITJAN: Androgen-primed chemotherapy—experimental confirmation of efficacy